Bioengineering a better adeno-associated virus vector for gene therapy

A new study characterizes a bioengineered adeno-associated virus (AAV)3B capsid variant that demonstrates improved transduction to human liver cells. Another advantage of the AAV3B-V04 capsid was its significantly reduced seroreactivity to human serum samples, as reported in the study published in the peer-reviewed journal Human Gene Therapy.